Stop or Replace: Effect of stopping sulfonylureas or replacing sulfonylureas with a dipeptidyl peptidase 4 (DPP-IV) inhibitor in Type 2 diabetes patients on pre-mix insulin.
Phase 4
- Conditions
- type 2 diabetesMetabolic and Endocrine - Diabetes
- Registration Number
- ACTRN12615000732583
- Lead Sponsor
- St Vincent's Hospital Sydney
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 99
Inclusion Criteria
Diagnosed with type 2 diabetes
- Taking sulfonylurea since > 4 years
- Taking NovoMix30 or HumalogMix25 at least twice daily since more than 6 months
- Stable dose of current regular medication in last 4 weeks
Exclusion Criteria
- HbA1c > 8.5%
- Already on DPP-4 inhibitor
- Intolerance or contraindication to DPP-4 inhibitors
- Unstable micro- or macrovascular complications within last 3 months
- Non-adherence to medications or glucose monitoring
- Type 1 diabetes
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method